Shilpa Medicare Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Shilpa Medicare and mAbTree Biologics receive FDA Orphan Drug Designation, Advancing Treatment for Rare Blood Cancers".
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare, along with its partner mAbTree Biologics, has received an Orphan Drug Designation from the U.S. FDA for a therapy aimed at treating rare blood cancers. The designation was announced via a press release dated January 28, 2026, and shared with the stock exchange as a regulatory disclosure. Orphan Drug Designation is granted by the FDA to drugs intended to treat rare diseases affecting fewer than 200,000 people in the U.S., and it comes with incentives such as 7 years of market exclusivity, tax credits on clinical trials, and waived FDA application fees. No specific financial figures, drug names, or timelines for trials/launch were disclosed in this filing.
This is a positive regulatory milestone that validates Shilpa Medicare's biologics pipeline and strengthens its U.S. market prospects. Shareholders may view this as a sentiment-boosting development, though the actual financial impact depends on future trial results and commercialisation timelines.